X0609 4 2026-09-02 true 0001974640 Apogee Therapeutics, Inc. APGE 0001983476 Dambkowski Carl false C/O APOGEE THERAPEUTICS, INC. 1 LETTERMAN DRIVE, BUILDING B SAN FRANCISCO CA 94129 true Chief Medical Officer false Common Stock 2026-09-02 4 D 0 1375 135.06 D 167123 D Common Stock 2026-09-03 4 D 0 167123 D 0 D Stock Option (Right to Buy) 22.86 2026-09-03 4 D 0 110665 D 2033-12-18 Common Stock 110665 0 D Stock Option (Right to Buy) 49.07 2026-09-03 4 D 0 124962 D 2034-12-09 Common Stock 124962 0 D Stock Option (Right to Buy) 75.78 2026-09-03 4 D 0 83690 D 2036-01-02 Common Stock 83690 0 D The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. /s/ Matthew Batters, as attorney-in-fact for Carl Dambkowski 2026-09-03